EMEA: Questions and answers on the review of bisphosphonates and the risk of osteonecrosis of the jaw

The European Medicines Agency has completed a review on the risk of osteonecrosis (death of bone tissue) of the jaw associated with the use of bisphosphonates. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that there is an increased risk of osteonecrosis of the jaw in patients using these medicines.